Wanbang Of China To Develop D-Pharm Anti-Stroke Drug From Phase III
This article was originally published in PharmAsia News
Executive Summary
China's Wanbang Biopharmaceuticals, the nation's largest insulin maker, has signed an agreement with Israel's D-Pharm to develop drugs to prevent strokes in China. Wanbang is to begin by covering the cost of the Phase III trials already under way for D-Pharm's DP-b99 membrane active chelator drug. Wanbang also is to pay D-Pharm up to $25.5 million if the drug gets approved, and then will pay royalties. (Click here for more